<DOC>
	<DOCNO>NCT00233402</DOCNO>
	<brief_summary>The purpose study document additional detection papillary bladder cancer reduce early recurrence due improve detection resection tumor Hexvix cystoscopy compare standard cystoscopy patient papillary bladder cancer .</brief_summary>
	<brief_title>Study Improve Detection Early Recurrence Rate Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy</brief_title>
	<detailed_description>In superficial bladder cancer macroscopic tumor include non-invasive papillary tumor ( Ta ) bladder relatively easy visualize cystoscopic examination white light . However , dysplasia , carcinoma situ ( CIS ) small exophytic tumor easily overlook . These lesion predictive recurrence progression disease , identification lesion crucial factor prognosis patient . The present situation 50-75 % recurrence rate show inadequacy white light cystoscopy detection resection lesion . A good detection papillary bladder cancer early detection CIS lesion provide patient complete TURB , optimal pharmacological treatment need , may reduce need follow cystoscopies hopefully result good prognosis patient . The aim present study compare Hexvix cystoscopy white light cystoscopy detection histology confirm papillary bladder cancer patient papillary bladder cancer compare early recurrence rate Hexvix white light transurethral resection ( TURB ) white light TURB patient superficial bladder cancer .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>The patient indicate cystoscopic examination suspect verified papillary bladder cancer fulfill one follow criterion : Patients one initial bladder tumor confirm outpatient cystoscopy . Patients recurrence within 12 month confirm outpatient cystoscopy Patients one papillary lesion recurrence independently time recurrence confirm outpatient cystoscopy Patients know tumor prostatic urethra distal urethra Gross hematuria . ( Note : Gross hematuria define heavy bladder bleed result marked amount blood urine , may interfere fluorescence cystoscopy . Where bleed light , patient exclude investigator 's opinion , rinse cystoscopy alleviate possible interference fluorescence cystoscopy ) . Patient porphyria . Known allergy hexyl aminolevulinate hydrochloride similar compound . Participation clinical study investigational drug either concurrently within last 30 day . Pregnant breastfeeding ( woman childbearing potential must document negative serum urine pregnancy test screening use contraceptive pill intrauterine device ( IUD ) treatment least one month thereafter ) . Patients receive BCG chemotherapy within three month prior initial cystoscopy/TURB , except single dose chemotherapy prevention seed resection . Conditions associate risk poor protocol compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Hexvix</keyword>
	<keyword>Fluorescence</keyword>
	<keyword>Cystoscopy</keyword>
</DOC>